Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice

Hideaki Nakaya

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Thiazolidinediones are synthetic ligands for peroxisome proliferator activated receptor gamma. They have been demonstrated to possess cardioprotective effects in humans and antiatherogenic properties in animal models. We observed that atherosclerosis in low-density lipoprotein receptor null mice progressed when mice were fed a high-fat diet. Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease. However, pioglitazone, in combination with the withdrawal of a high-fat diet, was unable to reverse established atherosclerosis. These findings describe, in part, a general paradox of how therapeutic agents are evaluated in common murine models of atherosclerosis and the lack of therapeutic benefit of agents given to mice with established atherosclerotic lesions, and further, may have implications for human therapy.

Original languageEnglish
Pages (from-to)229-234
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Volume68
Issue number2
Publication statusPublished - 2010 Feb

Fingerprint

LDL Receptors
PPAR gamma
pioglitazone
Atherosclerosis
High Fat Diet
Thiazolidinediones
Therapeutics
Animal Models
Ligands

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice. / Nakaya, Hideaki.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 68, No. 2, 02.2010, p. 229-234.

Research output: Contribution to journalReview article

@article{e9463134ae0c4117b4665a4ba05488b5,
title = "Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice",
abstract = "Thiazolidinediones are synthetic ligands for peroxisome proliferator activated receptor gamma. They have been demonstrated to possess cardioprotective effects in humans and antiatherogenic properties in animal models. We observed that atherosclerosis in low-density lipoprotein receptor null mice progressed when mice were fed a high-fat diet. Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease. However, pioglitazone, in combination with the withdrawal of a high-fat diet, was unable to reverse established atherosclerosis. These findings describe, in part, a general paradox of how therapeutic agents are evaluated in common murine models of atherosclerosis and the lack of therapeutic benefit of agents given to mice with established atherosclerotic lesions, and further, may have implications for human therapy.",
author = "Hideaki Nakaya",
year = "2010",
month = "2",
language = "English",
volume = "68",
pages = "229--234",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "2",

}

TY - JOUR

T1 - Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice

AU - Nakaya, Hideaki

PY - 2010/2

Y1 - 2010/2

N2 - Thiazolidinediones are synthetic ligands for peroxisome proliferator activated receptor gamma. They have been demonstrated to possess cardioprotective effects in humans and antiatherogenic properties in animal models. We observed that atherosclerosis in low-density lipoprotein receptor null mice progressed when mice were fed a high-fat diet. Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease. However, pioglitazone, in combination with the withdrawal of a high-fat diet, was unable to reverse established atherosclerosis. These findings describe, in part, a general paradox of how therapeutic agents are evaluated in common murine models of atherosclerosis and the lack of therapeutic benefit of agents given to mice with established atherosclerotic lesions, and further, may have implications for human therapy.

AB - Thiazolidinediones are synthetic ligands for peroxisome proliferator activated receptor gamma. They have been demonstrated to possess cardioprotective effects in humans and antiatherogenic properties in animal models. We observed that atherosclerosis in low-density lipoprotein receptor null mice progressed when mice were fed a high-fat diet. Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease. However, pioglitazone, in combination with the withdrawal of a high-fat diet, was unable to reverse established atherosclerosis. These findings describe, in part, a general paradox of how therapeutic agents are evaluated in common murine models of atherosclerosis and the lack of therapeutic benefit of agents given to mice with established atherosclerotic lesions, and further, may have implications for human therapy.

UR - http://www.scopus.com/inward/record.url?scp=77949885156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949885156&partnerID=8YFLogxK

M3 - Review article

VL - 68

SP - 229

EP - 234

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 2

ER -